Overbrook Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
Overbrook Management's CLDX Position: Q3 2026 in Review
Overbrook Management held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 11,537 shares worth $374K. The position accounts for 0.06% of the portfolio, ranked #46.
Overbrook Management first reported a position in CLDX in Q2 2017 and has held it in 23 quarters since. The position peaked at $429K in Q2 2026. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Overbrook Management held 11,537 shares of Celldex Therapeutics worth $374K as of Q3 2026.
- Overbrook Management left its Celldex Therapeutics share count unchanged in Q3 2026.
- Celldex Therapeutics made up 0.06% of Overbrook Management's portfolio in Q3 2026, its #46 holding.
- Overbrook Management first reported a position in Celldex Therapeutics in Q2 2017 and has held it in 23 quarters since.
- Overbrook Management's Celldex Therapeutics position peaked at $429K in Q2 2026.
- 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Overbrook Management's 13F filing for Q3 2026, filed 8 Oct 2026.